NFE2L2 and hepatocellular carcinoma: In human HCC, CTNNB1 (Catenin b1; coding β-Catenin; 32.8%) and TP53 (20.8%) mutations are more frequent than NRF2. In the resistant hepatocyte model, β-catenin mutations were found in adenomas and HCCs only at the late-stage.